160 related articles for article (PubMed ID: 31438622)
1. Treatment with Soluble Activin Receptor Type IIB Alters Metabolic Response in Chemotherapy-Induced Cachexia.
O'Connell TM; Pin F; Couch ME; Bonetto A
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31438622
[TBL] [Abstract][Full Text] [Related]
2. Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
Hulmi JJ; Nissinen TA; Räsänen M; Degerman J; Lautaoja JH; Hemanthakumar KA; Backman JT; Ritvos O; Silvennoinen M; Kivelä R
J Cachexia Sarcopenia Muscle; 2018 Apr; 9(2):417-432. PubMed ID: 29230965
[TBL] [Abstract][Full Text] [Related]
3. ACVR2B/Fc counteracts chemotherapy-induced loss of muscle and bone mass.
Barreto R; Kitase Y; Matsumoto T; Pin F; Colston KC; Couch KE; O'Connell TM; Couch ME; Bonewald LF; Bonetto A
Sci Rep; 2017 Oct; 7(1):14470. PubMed ID: 29089584
[TBL] [Abstract][Full Text] [Related]
4. ACVR2B antagonism as a countermeasure to multi-organ perturbations in metastatic colorectal cancer cachexia.
Huot JR; Pin F; Narasimhan A; Novinger LJ; Keith AS; Zimmers TA; Willis MS; Bonetto A
J Cachexia Sarcopenia Muscle; 2020 Dec; 11(6):1779-1798. PubMed ID: 33200567
[TBL] [Abstract][Full Text] [Related]
5. Cachexia induced by cancer and chemotherapy yield distinct perturbations to energy metabolism.
Pin F; Barreto R; Couch ME; Bonetto A; O'Connell TM
J Cachexia Sarcopenia Muscle; 2019 Feb; 10(1):140-154. PubMed ID: 30680954
[TBL] [Abstract][Full Text] [Related]
6. The systemic activin response to pancreatic cancer: implications for effective cancer cachexia therapy.
Zhong X; Pons M; Poirier C; Jiang Y; Liu J; Sandusky GE; Shahda S; Nakeeb A; Schmidt CM; House MG; Ceppa EP; Zyromski NJ; Liu Y; Jiang G; Couch ME; Koniaris LG; Zimmers TA
J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1083-1101. PubMed ID: 31286691
[TBL] [Abstract][Full Text] [Related]
7. Muscle and serum metabolomes are dysregulated in colon-26 tumor-bearing mice despite amelioration of cachexia with activin receptor type 2B ligand blockade.
Lautaoja JH; Lalowski M; Nissinen TA; Hentilä J; Shi Y; Ritvos O; Cheng S; Hulmi JJ
Am J Physiol Endocrinol Metab; 2019 May; 316(5):E852-E865. PubMed ID: 30860875
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-related cachexia is associated with mitochondrial depletion and the activation of ERK1/2 and p38 MAPKs.
Barreto R; Waning DL; Gao H; Liu Y; Zimmers TA; Bonetto A
Oncotarget; 2016 Jul; 7(28):43442-43460. PubMed ID: 27259276
[TBL] [Abstract][Full Text] [Related]
9. Acute inhibition of myostatin-family proteins preserves skeletal muscle in mouse models of cancer cachexia.
Benny Klimek ME; Aydogdu T; Link MJ; Pons M; Koniaris LG; Zimmers TA
Biochem Biophys Res Commun; 2010 Jan; 391(3):1548-54. PubMed ID: 20036643
[TBL] [Abstract][Full Text] [Related]
10. Systemic blockade of ACVR2B ligands attenuates muscle wasting in ischemic heart failure without compromising cardiac function.
Szabó Z; Vainio L; Lin R; Swan J; Hulmi JJ; Rahtu-Korpela L; Serpi R; Laitinen M; Pasternack A; Ritvos O; Kerkelä R; Magga J
FASEB J; 2020 Aug; 34(8):9911-9924. PubMed ID: 32427381
[TBL] [Abstract][Full Text] [Related]
11. Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes.
Nissinen TA; Degerman J; Räsänen M; Poikonen AR; Koskinen S; Mervaala E; Pasternack A; Ritvos O; Kivelä R; Hulmi JJ
Sci Rep; 2016 Sep; 6():32695. PubMed ID: 27666826
[TBL] [Abstract][Full Text] [Related]
12. Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.
Nissinen TA; Hentilä J; Penna F; Lampinen A; Lautaoja JH; Fachada V; Holopainen T; Ritvos O; Kivelä R; Hulmi JJ
J Cachexia Sarcopenia Muscle; 2018 Jun; 9(3):514-529. PubMed ID: 29722201
[TBL] [Abstract][Full Text] [Related]
13. Systemic Blockade of ACVR2B Ligands Protects Myocardium from Acute Ischemia-Reperfusion Injury.
Magga J; Vainio L; Kilpiö T; Hulmi JJ; Taponen S; Lin R; Räsänen M; Szabó Z; Gao E; Rahtu-Korpela L; Alakoski T; Ulvila J; Laitinen M; Pasternack A; Koch WJ; Alitalo K; Kivelä R; Ritvos O; Kerkelä R
Mol Ther; 2019 Mar; 27(3):600-610. PubMed ID: 30765322
[TBL] [Abstract][Full Text] [Related]
14. Activin Receptor Ligand Blocking and Cancer Have Distinct Effects on Protein and Redox Homeostasis in Skeletal Muscle and Liver.
Hentilä J; Nissinen TA; Korkmaz A; Lensu S; Silvennoinen M; Pasternack A; Ritvos O; Atalay M; Hulmi JJ
Front Physiol; 2018; 9():1917. PubMed ID: 30713500
[TBL] [Abstract][Full Text] [Related]
15. A soluble activin receptor type IIB does not improve blood glucose in streptozotocin-treated mice.
Wang Q; Guo T; Portas J; McPherron AC
Int J Biol Sci; 2015; 11(2):199-208. PubMed ID: 25561902
[TBL] [Abstract][Full Text] [Related]
16. Generation of activin receptor type IIB isoform-specific hypomorphic alleles.
Lee YJ; Hong KH; Yun J; Oh SP
Genesis; 2006 Oct; 44(10):487-94. PubMed ID: 16991118
[TBL] [Abstract][Full Text] [Related]
17. Assessment of goat activin receptor type IIB knockdown by short hairpin RNAs in vitro.
Patel AK; Tripathi AK; Shah RK; Patel UA; Joshi CG
J Recept Signal Transduct Res; 2014 Dec; 34(6):506-12. PubMed ID: 24870261
[TBL] [Abstract][Full Text] [Related]
18. Metabolic derangements of skeletal muscle from a murine model of glioma cachexia.
Cui P; Shao W; Huang C; Wu CJ; Jiang B; Lin D
Skelet Muscle; 2019 Jan; 9(1):3. PubMed ID: 30635036
[TBL] [Abstract][Full Text] [Related]
19. Goat activin receptor type IIB knockdown by artificial microRNAs in vitro.
Patel AK; Shah RK; Parikh IK; Joshi CG
Appl Biochem Biotechnol; 2014 Sep; 174(1):424-36. PubMed ID: 25080379
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
